Manufacturers of biologics for rare diseases face unique commercialization challenges at odds with the model of low-cost, bulk product distribution. Information is key down the line: patients and advocates need guidance about the products’ therapeutic benefit and assistance programs; manufacturers need patient input for marketing and education campaigns; payers need notice about the products’ high cost and evidence supporting coverage, payment, and usage; physicians and staff need payment assurance from payers and knowledge of assistance programs so patients have product access. This panel will feature, biologic marketing and commercialization experts and a patient advocate sharing insights about navigating these challenges.

Learning Objectives:

• Explore distribution, partnership and reimburement challenges facing manufacturers of orphan drugs
• Identify best practices for commercializing orphan drugs gleaned from experienced executives
• Develop strategies for partnering with both patients and their advocates

Ability Level: All

Session ID: 2006